The "anecdotal" evidence of reversal of disease out of Austrailia is astounding. The professional level of AVXL management and advisory board gives me confidence that there is no hoax or deception in these reports.
On that basis I believe that approval is nearly certain given the high safety profile of 2-73. I also expect the speed of approval to be unprecedented due to need.
If 2-73 or 3-71 or another molecule in anavex"s arsenal receives FDA for a single indication you will see price appreciation from this level ( you will receive a return on your investment ). Now you decide what that chance is .I'm betting pretty good or at the very least risk / reward is exceptionally compelling at this level.
Shouldn't be too hard to figure - In Phase-2 for Alzheimer's with an FDA nod to move to Phase-3, ANAVEX is way underpriced!! If it was me, I would buy with 2-hands in the ridiculous $4 level we are in. When news hits. we should be much higher. Chances are much greater for an upward surge with great data or partnership. Go for it!!!!!! Good Luck
News 
Market Data 
Discover 
AI
